Here are five things to know:
1. The procedure replaces degenerated or injured intervertebral discs with the Mobi-C Cervical Disc, the only cervical disc approved by the FDA to treat more than one disc level of the cervical spine.
2. Disc degeneration reduces padding to absorb stress put on the spine, often causing back pain and a need for treatment through spinal fusion or disc replacement.
3. While disc fusion often causes loss of motion and even the need for additional surgeries, the Mobi-C device allows the neck to maintain normal motion and prevent adjacent disc level degeneration.
4. The product’s FDA clinical trial involved 599 patients and demonstrated a 69.7 percent success rate compared to traditional fusion results of 37.4 percent.
5. After 24 months, results showed that patients who received the two-level cervical disc replacement during the trial phase returned to work an average of three weeks earlier than those who were treated with traditional cervical fusion. They also showed reduced rates of adjacent spinal segment degeneration and lower rates of additional surgeries.
More device articles:
Stryker, K2M, SI-Bone & more: 17 device company key notes
Germany dominates European total ankle replacement market — 6 points
Global cervical total disc replacement device market to see growth in ASC sector: 7 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.